Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $97.33

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $97.3333.

ARWR has been the subject of several analyst reports. Piper Sandler reiterated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. JPMorgan Chase & Co. upped their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. HC Wainwright increased their price target on Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Leerink Partners boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th.

Arrowhead Pharmaceuticals Trading Up 1.0%

NASDAQ ARWR opened at $89.24 on Friday. Arrowhead Pharmaceuticals has a 52 week low of $17.22 and a 52 week high of $95.49. The company has a 50 day moving average price of $80.60 and a 200 day moving average price of $71.80. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm has a market cap of $12.57 billion, a PE ratio of -39.66 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter last year, the business earned ($1.26) earnings per share. Arrowhead Pharmaceuticals’s revenue was up 171.0% on a year-over-year basis. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Trading of Arrowhead Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Versant Capital Management Inc raised its holdings in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $25,000. Optiver Holding B.V. grew its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares during the last quarter. Finally, First Horizon Corp acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.